HER2 Positive - An Extension Study of Trastusumab Emtansine in Patients Previously Treated With Trastusumab Emtansine

This is a global, multicenter, open-label extension study. Patients receiving single-agent T-DM1 or combination T-DM1 administered in combination with paclitaxel or with pertuzumab ± paclitaxel in a Genentech/Roche-sponsored study who completed the parent study or who continue to receive study drug(s) at the time of the parent study closure are eligible for continued treatment on this protocol.

See detailed information including eligibility.

Cancer, Adult Breast Cancer